Advice

In the absence of a submission from the holder of the marketing authorisation:

esketamine (Spravato®) is not recommended for use within NHSScotland.

Indication under review: Co-administered with oral antidepressant therapy, in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Download detailed advice622KB (PDF)

Download

Medicine details

Medicine name:
esketamine (Spravato®)
SMC ID:
SMC2539
Indication:

Co-administered with oral antidepressant therapy, in adults with a moderate to severe episode of Major Depressive Disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Central nervous system
Submission type
Non submission
Status
Not recommended
Date advice published
07 November 2022